News for RedHill Biopharma Stock (RDHL)

RedHill's (RDHL) Opaganib Effective Against Kidney Fibrosis

Zacks Investment Research • 09/08/21

RedHill Biopharma notes study demonstrates opaganib's efficacy in significantly decreasing renal fibrosis

Proactive Investors • 09/08/21

RedHill Unveils New Movantik Data For Opioid-Induced Constipation

Benzinga • 09/07/21

RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis

PRNewsWire • 09/07/21

RedHill Biopharma Ltd Announces New Movantik Analyses at PAINWeek

Accesswire • 09/07/21

RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021

PRNewsWire • 09/07/21

RedHill to Present at HCW & Cantor Conferences

Accesswire • 09/02/21

RedHill Biopharma to Present at H.C. Wainwright Annual Global Investment and Cantor Global Healthcare Conferences

PRNewsWire • 09/02/21

Why RedHill Biopharma Stock Jumped on Tuesday

The Motley Fool • 08/31/21

Cantor Sees 'Compelling Investment Opportunity' In This Biopharma

Benzinga • 08/31/21

RedHill Biopharma Ltd. (RDHL) CEO Dror Ben-Asher on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha • 08/26/21

RedHill Biopharma reports second quarter 2021 results, showing record quarterly revenues

Proactive Investors • 08/26/21

RedHill Biopharma's Oral COVID-19 Candidate Shows Preclinical Action Against Delta Variant

Benzinga • 08/26/21

RedHill Biopharma demonstrates strong inhibition by opaganib of the coronavirus (COVID-19) Delta variant

Proactive Investors • 08/26/21

Redhill Biopharma: Q2 Earnings Insights

Benzinga • 08/26/21

RedHill Reports Second Quarter 2021 Results

Accesswire • 08/26/21

RedHill Biopharma Reports Second Quarter 2021 Financial Results and Operational Highlights

PRNewsWire • 08/26/21

RedHill Biopharma Ltd Announces RedHill's Opaganib Strong Delta Variant Inhibition

Accesswire • 08/26/21

RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant

PRNewsWire • 08/26/21

A Preview Of Redhill Biopharma's Earnings

Benzinga • 08/25/21

RedHill Biopharma says USPTO has issued it with two new patents for opaganib for Ebola Virus and RHB-104 for Crohn's

Proactive Investors • 08/23/21

RedHill Announces Two New U.S. Patents

Accesswire • 08/23/21

RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn's

PRNewsWire • 08/23/21

RedHill Biopharma to Host Second Quarter 2021 Financial Results and Operational Highlights Webcast on August 26, 2021

PRNewsWire • 08/19/21

RedHill Settles Movantik(R) Apotex Patent Litigation

Accesswire • 07/22/21